|
RS: Mean, median (range)
|
7, 8 (0–10)
|
14, 14 (11–17)
|
11, 12 (0–17)
|
|
Age at diagnosis
|
|
Mean, median (range); years
|
58, 59 (25–84)
|
58, 57 (22–90)
|
58, 58 (22–90)
|
|
< 40 years; n (%)
|
19 (4.1%)
|
21 (2.9%)
|
40 (3.4%)
|
|
40–49 years; n (%)
|
98 (21.2%)
|
156 (21.6%)
|
254 (21.5%)
|
|
≥ 50 years; n (%)
|
345 (74.7%)
|
545 (75.5%)
|
890 (75.2%)
|
|
Tumor size, median (range); cm
|
1.28, 1.1 (0.35–5.5)
|
1.28, 1.1 (0.3–4.5)
|
1.28, 1.1 (0.3–5.5)
|
|
Multifocality; n (%)
|
106 (22.9%)
|
128 (17.7%)
|
234 (19.8%)
|
|
LVI; n (%)
|
72 (15.6%)
|
126 (17.5%)
|
198 (16.7%)
|
|
Local treatment; n (%)
|
|
BCS only
|
12 (2.6%)
|
28 (3.9%)
|
40 (3.4%)
|
|
BCS and radiation therapy
|
301 (65.2%)
|
515 (71.3%)
|
816 (68.9%)
|
|
Total mastectomy
|
149 (32.3%)
|
177 (24.5%)
|
326 (27.5%)
|
|
Total mastectomy and radiation therapy
|
0
|
2 (0.3%)
|
2 (0.2%)
|
|
LRR; n (%)
|
3 (0.6%)
|
5 (0.7%)
|
8 (0.7%)
|
|
Median follow-up (range); months
|
51.7 (0.9–108.3)
|
51.3 (1–93)
|
51.4 (0.9–108.3)
|
